This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

KYTHERA Biopharmaceuticals, Inc. To Present New Data At 2013 American Academy Of Dermatology (AAD) Annual Meeting Demonstrating Results For ATX-101 In The Reduction Of Submental Fat (SMF) Or “Double Chin”

Stocks in this article: KYTH

KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced four abstracts will be presented at the 71 st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla. The abstracts, including one to be presented at the Late Breaking Research Symposium on March 2, evaluate the safety, efficacy and pharmacokinetics of ATX-101, an investigational injectable drug being studied for the nonsurgical reduction of submental fat (SMF), commonly known as the double chin. The ATX-101 global clinical development program has enrolled more than 2,500 total patients of which more than 1,500 have been treated with ATX-101.

The abstracts include:

  • ATX-101 (deoxycholic acid injection) for the reduction of submental fat: Interim results from a multicenter, 12-month, open-label study (Late Breaking Research Symposium)
  • ATX-101 for the reduction of double chin caused by submental fat: Results from the ATX-101-10-16 European phase III study (Poster: P6257, available March 1)
  • Reduction of double chin caused by submental fat with ATX-101: Results from the ATX-101-10-17 European phase III study (Poster: P6256, available March 1)
  • Open-label pharmacokinetic study to evaluate lipid levels in the blood following injections of ATX-101 (deoxycholic acid) (Poster: P5917, available March 1)

“KYTHERA Biopharmaceuticals is at the forefront of addressing the unmet need for a safe, clinically proven injectable drug for the reduction of undesirable submental fat,” said Keith Leonard, president and chief executive officer, KYTHERA Biopharmaceuticals, Inc. “The data being presented this week further supports the scientific and clinical rigor of the ATX-101 development program. We look forward to the final results of our Phase III trials and potentially entering the market with this important first-in-class aesthetic drug.”

The complete abstracts can be found in the April 2013 supplement to the Journal of the American Academy of Dermatology ( JAAD), volume 68, number 4.

About ATX-101

ATX-101 is a potential first-in-class injectable drug candidate under clinical investigation for the reduction of unwanted submental fat. ATX-101 is a proprietary formulation of synthetic deoxycholic acid, a well-characterized endogenous compound that is present in the body to promote the natural breakdown of dietary fat. ATX-101 is designed to be a locally-injected drug that causes proximal, preferential destruction of adipocytes, or fat cells, with minimal effect on surrounding tissue. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and durable results in the reduction of submental fat, which commonly presents as an undesirable “double chin.” These results correspond with subject satisfaction measures demonstrating meaningful improvement in perceived chin appearance.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs